KCNB2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL29793705	1.00	1/20
SCHEMBL28402250	0.83	1/20
SCHEMBL28413523	0.73	1/20
SCHEMBL28413244	0.71	1/20
SCHEMBL16583815	0.69	1/20
SCHEMBL28405947	0.69	1/20
SCHEMBL28410953	0.68	1/20
SCHEMBL28257362	0.66	1/20
SCHEMBL29793887	0.66	1/20
SCHEMBL28257357	0.66	1/20
SCHEMBL28413196	0.66	1/20
SCHEMBL28408170	0.65	1/20
SCHEMBL28408036	0.63	1/20
SCHEMBL28402758	0.63	1/20
SCHEMBL29494399	0.61	1/20
SCHEMBL28257375	0.61	1/20
SCHEMBL28402258	0.61	1/20
SCHEMBL28402273	0.60	1/20
SCHEMBL14521781	0.60	1/20
SCHEMBL28257359	0.59	1/20

Clinical trials — most relevant to KCNB2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery	PHASE4	RECRUITING
Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study	PHASE4	COMPLETED
Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease	PHASE4	NOT_YET_RECRUITING
Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study	PHASE3	COMPLETED
Mutation-specific Therapy for the Long QT Syndrome	PHASE2	COMPLETED
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy	PHASE1/PHASE2	RECRUITING
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients	PHASE2	COMPLETED
N-of-1 in ATS and MEPPC	PHASE2	NOT_YET_RECRUITING
Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss	PHASE2	COMPLETED
4-Aminopyridine in Episodic Ataxia Type 2	PHASE2	WITHDRAWN
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK	PHASE1	COMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy	nan	UNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism	nan	COMPLETED
Qatar Cardiovascular Biorepository of AF Patients	nan	UNKNOWN
The Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats	nan	COMPLETED
The Effects of the Anesthetic Drug Propofol on the Way the Heart Recovers Between Beats	nan	COMPLETED
Characteristics of Andersen-Tawil Syndrome	nan	COMPLETED
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia	nan	UNKNOWN
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.	nan	UNKNOWN
Identify the Genes Polymorphisms Related to Non-familial Bradyarrhythmia	nan	UNKNOWN
ST-segment Elevation as an AF Endophenotype	nan	COMPLETED
Characteristics of Episodic Ataxia Syndrome	nan	COMPLETED
Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome	nan	RECRUITING
Factors Affecting Salt Intake in Young Adults	nan	UNKNOWN
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services	nan	UNKNOWN
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA)	nan	UNKNOWN
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a KCNB2 binder may also engage these)

Protein	Name	Similarity
Q63099	—	1.000	Q63099 →
A6H8H5	—	1.000	A6H8H5 →
Q4ZHA6	—	1.000	Q4ZHA6 →
KCNB1	Potassium voltage-gated channel subfamily B member 1	1.000	landscape →
Q95167	—	1.000	Q95167 →
Q95L11	—	1.000	Q95L11 →
Q03717	—	0.997	Q03717 →
O18868	—	0.992	O18868 →
KCNQ5	Potassium voltage-gated channel subfamily KQT member 5	0.992	landscape →
P15387	—	0.992	P15387 →
Q9MZ19	—	0.991	Q9MZ19 →
Q9TTJ7	—	0.990	Q9TTJ7 →
Q9Z351	—	0.990	Q9Z351 →
KCND3	A-type voltage-gated potassium channel KCND3	0.989	landscape →
P25122	—	0.988	P25122 →
KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	0.987	landscape →
Q6DN90	—	0.987	Q6DN90 →
Q5RHD1	—	0.986	Q5RHD1 →
P22462	—	0.986	P22462 →
O70344	—	0.986	O70344 →
A5PLL1	—	0.985	A5PLL1 →
A4Q9E8	—	0.985	A4Q9E8 →
O54852	—	0.985	O54852 →
Q6IVY4	—	0.985	Q6IVY4 →
O54928	—	0.985	O54928 →
Q5PQX1	—	0.985	Q5PQX1 →
Q8K3I4	—	0.985	Q8K3I4 →
O54828	—	0.984	O54828 →
O88943	—	0.984	O88943 →
Q03721	—	0.984	Q03721 →